

Asthma Indicators for LHIN 14: North West

Indicator	Asthma Indicators for LHIN 14: North West																						
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma) [†]	35.26	38.98	40.61	43.91	45.54	44.52	49.18	50.41	47.98	51.67	57.02	54.99	57.40	56.70	62.05	61.91	60.42	66.12	63.32	63.29	62.24	56.14	57.71
2. PFT used for monitoring (% of prevalent asthma) [†]	9.86	8.19	8.21	7.63	8.67	8.12	7.13	6.92	6.39	6.40	6.70	6.58	6.37	6.36	6.38	6.41	6.39	6.00	6.11	6.08	5.99	5.82	4.85
3. ≥1 ICS prescription (% of prevalent asthma) [‡]	60.50	59.00	57.91	56.98	57.73	55.26	54.99	54.77	52.40	51.29	52.78	52.86	52.76	51.89	52.66	52.31	49.88	50.29	49.72	49.01	47.25	44.19	40.75
4. ≥1 β2-agonist prescription (% of prevalent asthma) [‡]	64.94	64.92	64.25	61.36	62.48	59.17	58.18	56.19	54.30	51.10	50.24	50.17	47.30	45.10	44.93	45.64	43.14	43.62	40.37	22.94	21.97	19.63	20.93
5. ≥1 asthma ED visit (% of prevalent asthma)	7.77	6.47	5.06	4.55	4.55	4.25	4.39	3.88	3.52	3.15	3.34	3.43	2.92	2.69	2.64	2.30	2.18	2.15	1.89	1.97	1.86	1.79	1.53
6. ≥1 asthma physician office visit (% of prevalent asthma)	30.13	27.57	24.89	23.44	22.64	18.68	17.51	16.48	15.66	15.06	14.31	12.79	11.67	10.28	10.32	9.42	8.62	8.15	8.05	8.58	8.58	7.46	7.02
7. β2-agonist use (% of prevalent asthma) [‡]																							
0	35.06	35.08	35.75	38.64	37.52	40.83	41.82	43.81	45.70	48.90	49.76	49.83	52.70	54.90	55.07	54.36	56.86	56.38	59.63	77.06	78.03	80.37	79.07
1-2	16.78	18.00	19.05	17.16	19.17	17.42	17.39	17.51	17.57	16.84	16.94	18.30	19.16	18.81	18.99	19.97	18.68	19.27	18.80	11.80	10.44	9.06	9.69
≥3	48.16	46.92	45.20	44.20	43.32	41.75	40.79	38.68	36.73	34.25	33.30	31.88	28.15	26.29	25.94	25.67	24.46	24.35	21.57	11.14	11.53	10.57	11.24

*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

[†]PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

[‡]Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

Technical notes:

^aOHIP data was up to December 2019 when the tables were created.

^bFor asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

^cIndividuals with missing LHIN, rurality, or without OHIP coverage were excluded.

^dAsthma incidence of the year were excluded from this table, except for indicator 1.

^eIndex date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date^{a-c}
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date^{a,c-e}
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date^{c-e}
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date^{c-e}
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date^{c-e}
6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date^{c-e}
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above^{c,d}

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.